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Prior to October 1994 in the United States, botanical substances were regulated as 
ingredients of drug products, both over-the-counter (OTC) and prescription (Rx), or as 
components of food products. Most of the thousands of medicinal plant species in global 
commerce were not expressly permitted for use in food products. This fact, coupled with the 
reality that the U.S. Food and Drug Administration (FDA) had established panels to review all 
old drugs and establish new monographs, led to the eventual re-classification of most botanicals 
as non-monograph. Thus, by the early 1990’s many botanicals had no safe harbor, as they were 
determined to be unlawful for use as components of both foods and drugs.  
The tension caused by these facts is a backdrop, that leads to the U.S. Congress 
establishing a new regulatory framework, between food and drug, the Dietary Supplement Health 
and Education Act of 1994 (DSHEA). With the passage of DSHEA, most herbs of commerce, if 
intended for oral ingestion, became “old dietary ingredients” and could now be marketed with 
“nutrient content” or “structure function” claim statements. Botanicals intended for topical 
application were not protected by DSHEA however, and, for the most part, transitioned to use in 
non-drug cosmetic products, with the exception of a few that remained in the FDA monographs. 
Post-DSHEA, the U.S. market for herbal supplements boomed and continues to grow. 
This paper examines the impacts of DSHEA, 25-years on, on the ever-increasing market demand 
for botanical ingredients, including legal and regulatory issues (state, federal, and international) 
affecting production, import, trade and use of botanical supplement ingredients, and the 
necessary developments of (a) quality management systems such as good agricultural and 
collection practices (GACPs) linked to good manufacturing practices (GMPs); (b) ingredient 
quality standards such as pharmacopoeial monographs that can serve as the basis of 
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specifications for testing composition, identity, purity, and strength; (c) conservation status 
assessments of popular species, as many are obtained through wild-collection; and (d) standards 
(national and voluntary) for sustainable agriculture and wild collection practices in order to meet 
increasing market demand without detriment to biodiversity.   
Key words: Biodiversity; Botanical supplements; Conservation; Quality management, 
Sustainable production. 
Abbreviations: ABC, American Botanical Council; AHP, American Herbal Pharmacopoeia; 
AHPA, American Herbal Products Association; CBD, Convention on Biological Diversity; CFR, 
Code of Federal Regulations; CITES, Convention on International Trade in Endangered Species; 
CR, Critically Endangered; DSHEA, Dietary Supplement Health and Education Act of 1994; E, 
Endangered; EPA, U.S. Environmental Protection Agency; FCC, Food Chemicals Codex; FDA, 
U.S. Food and Drug Administration; FD&C Act, Federal Food, Drug, and Cosmetic Act; FEMA, 
Flavor and Extract Manufacturers Association; FLO, Fair Trade International; FR, Federal 
Register; FSMA, Food Safety Modernization Act; FWF, FairWild Foundation; JECFA, The Joint 
Expert Committee on Food Additives; GACP, Good Agricultural and Collection Practices; 
GMP, Good Manufacturing Practices; GRAS, Generally Recognized as Safe; GRASE, Generally 
Recognized as Safe & Effective; HARPC, Hazard Analysis and Risk-Based Preventive Controls; 
IUCN, International Union for Conservation of Nature; LC, Least Concern, MAP, Medicinal and 
Aromatic Plants; MPWG, Medicinal Plant Working Group (of USFWS); MPSG, Medicinal 
Plant Specialist Group (of IUCN); NOP, National Organic Program; NT, Near Threatened; OTC, 
Over-the-counter drug product; R, Rare; UEBT, Union for Ethical BioTrade; UpS, United Plant 
Savers; USC, U.S. Congress; USDA, U.S. Department of Agriculture; USFWS, U.S. Fish and 
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Wildlife Service; USP-NF, U.S. Pharmacopeia and National Formulary; VSS, Voluntary 
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A. Pre-DSHEA Regulatory Landscape 
In the United States (U.S.), prior to the passage of the Dietary Supplement Health and 
Education Act of 1994 (DSHEA) (USC 1994), botanicals were regulated as either botanical drug 
ingredients (over-the-counter (OTC) or prescription (Rx)), as non-drug cosmetic ingredients, or 
as conventional food ingredients. There was no middle ground between drug and food.  
A famous case that begged for a middle ground began in 1988, when a shipment of black 
currant (Ribes nigrum L.) seed oil from England was seized by U.S. Marshals. The U.S. Food 
and Drug Administration (FDA) argued that by merely filling the seed oil into gelatin capsules, 
the botanical substance would become an unsafe food additive and therefore an adulterated food, 
i.e. the gelatin capsule being the food. In 1991, the U.S. District Court for the Central District of 
Illinois ruled in favor the importing company and dismissed the case. In 1992, the FDA appealed 
the decision to the United States Court of Appeals for the Seventh Circuit. In January 1993, the 
appeals court affirmed the lower court decision, again, in favor of the importing company 
(Blumenthal 1994a). 
For a botanical to have been permitted for use as a food ingredient, it required FDA 
classification as either a (1) Generally Recognized as Safe (GRAS) substance (listed in FDA 
regulations, Title 21 Code of Federal Regulations [21 CFR], Parts 182 and 184); or, as a (2) food 
additive or color additive (listed in 21 CFR Parts 172, 173 and Parts 73, 74, respectively), and/or 
flavoring substance evaluated by the Flavor and Extract Manufacturers Association (FEMA) and 
the Joint Expert Committee on Food Additives (JECFA); or, as a (3) prior-sanctioned substance, 




While many botanical substances had been classified as old drugs, i.e. as active ingredients 
of medicinal products sold from the early 19
th
 century through the late 20
th
 century, in the mid-
1970’s, the FDA established expert review panels for the purposes of assessing the available 
evidence of safety and efficacy for all existing OTC drug active ingredients and establishing new 
labeling standards monographs. This process included the review of hundreds of “old” botanical 
drugs that were still on the pharmacy shelves in the 1970’s. This is an important fact to consider 
in the historical context that led to the creation of DSHEA in the 1990’s. From the mid-1970’s 
through the mid-1990’s, most botanical substances listed in FDA’s proposed and tentative final 
monographs were removed, due to the agency’s inability (at that time) to determine sufficient 
levels of evidence to support the claimed therapeutic uses. It is worth noting, however, that 
during the same time frame, other national health authorities (notably the German Federal Health 
Office (BGA)), were publishing positive therapeutic monographs for many of the same botanical 
drugs. Levels of evidence were defined differently in different countries. FDA’s reclassification 
of many important botanicals as “non-monograph” created a tension between industry and 
government. Suddenly non-monograph botanicals had no safe-harbor for market access, as they 
were determined to be unlawful for use as components of both foods and drugs. 
In 1992, as a strategy to address the issue, the European-American Phytomedicines Coalition 
(EAPC), a group of European and American phytomedicine manufacturers petitioned the FDA to 
expand its review of OTC drugs “to include products that have a long and safe history of use as 
nonprescription drugs in Western Europe.” To no avail, the EAPC subsequently filed two 
citizens' petitions with the FDA, to allow the sale of (1) valerian as an OTC nighttime sleep aid; 
and (2) ginger as an OTC antiemetic drug product (Blumenthal 1994, 1995). 
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Also in 1992, the American Herbal Products Association (AHPA) listed about 550 botanical 
species in their Herbs of Commerce, the majority of which had evidence of acceptable uses in 
food products (e.g. species listed in 21CFR, Parts172.5100,182.10 and 182.20), although the 
AHPA list also included species that were used only as botanical drugs (Foster 1992). In 1997, 
the FDA incorporated the AHPA list into regulation (21 CFR §101.4), requiring that the common 
or usual name of ingredients of dietary supplements (algal, botanical, and fungal) shall be 
consistent with the names standardized in the 1992 version of Herbs of Commerce (FDA 1997). 
The second edition of AHPA’s Herbs of Commerce increased the estimated number of species in 
U.S. commerce to 2,048 (AHPA 2000), and, in 2007, the International Union for Conservation of 
Nature (IUCN) estimated that about 3,000 medicinal and aromatic plant (MAP) species were in 
import-export trade (IUCN 2007). The point being that, of the thousands of herbs of commerce, 
most were not expressly listed as permitted for use in conventional food products. And, given the 
fact that only 2 new botanical drugs (out of over 600 applications) have been approved by the 
FDA in the 25 years since DSHEA, most botanicals must continue to navigate the middle ground 
between drug and food, as botanical dietary supplements. Both of the recently approved 
botanical drugs are prescription-only medicines with narrow indications for use, (1) an ointment 
containing a partially purified extract of green tea (Camellia sinensis (L.) Kuntze) leaf for 
treating genital/perianal warts, approved in 2006, and (2) a preparation of dragon’s blood 
(Croton lechleri Müll.Arg.) latex for treating HIV-related diarrhea, approved in 2012 (Wu 2017). 
After the passage of DSHEA, most oral ingestion herbal medicinal products transitioned to 
labeling as per the newly established dietary supplement subset of food regulations. However, 
the new regulatory framework provided no safe harbor for topical application botanical 
substances. While several of these did remain as Generally Recognized as Safe and Effective 
4 
 
(GRASE) active ingredients in FDA tentative-final monographs in the Federal Register (FR) or 
final monographs in the Code of Federal Regulations (CFR), e.g. Capsicum Oleoresin USP, 
Cocoa Butter NF, Colloidal Oatmeal USP, Topical Starch USP, and Witch Hazel USP, most 
external application botanical products in the market transitioned to non-drug cosmetic labeling.  
B. Post-DSHEA Market Boom 
The botanical ingredient sector experienced an initial market boom due to the fact that 
DSHEA removed considerable market access barriers and afforded the opportunity to make 
claim statements on labeling, including many formerly OTC drug monograph structure function 
claim statements. At first, the boom benefited a range of clinically-tested herbal extract products 
that already had marketing authorizations as OTC medicines in European countries and in 
neighboring Canada. These same herbal medicinal products quickly poured into the U.S. market, 
although labeled as dietary supplement products rather than as medicines. At the same time, 
scores of lower-cost look-alike products entered the market making it difficult for consumers to 
differentiate the good from the bad. It wasn’t unusual in the 1990’s to read market reports of 
ginseng (Panax spp.) product retail sales increasing by nearly 250% over previous year (Anon 
1994) or St. John’s wort (Hypericum perforatum L.) product sales increasing by over 2,800% 
from 1997 to 1998 (Brevoort 1998). 
Although the top botanical products of the 1990’s had relatively stable markets established in 
Europe, the new rapidly increasing market demand in the U.S. stimulated by the passage of 
DSHEA triggered considerable supply chain challenges, in terms of both quality and quantity. 
Suppliers of botanical raw materials spent the 1990’s scaling up production to keep up with 
spikes in demand, significantly increasing farm acreage and wild collection areas. But, then, 
booms do lead to busts, which hit the sector hard by the end of the decade. While the top-selling 
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botanical supplements of the 1990’s are still important today, their rankings have dropped and 
stabilized as new entries have displaced them. For example, turmeric (Curcuma longa L.) 
rhizome supplements are top-sellers today but were unheard of in the 1990’s. Table 1 shows the 
top-selling botanical supplement products in the U.S. mass market in 1998 compared with their 
rankings in 2017. 
Table 1: Top-selling botanical supplements – U.S. Mass Market – 1998 vs. 2017 ranking 
Primary ingredient(s) of supplement 1998 ranking 2017 ranking 
Ginkgo (Ginkgo biloba L.)  1 21 
St. John’s wort (Hypericum perforatum L.)  2 37 
Ginseng (Panax ginseng C.A.Mey. or P. quinquefolius L.) 3 25 
Garlic (Allium sativum L.) 4 18 
Echinacea (Echinacea angustifolia DC., E. pallida (Nutt.) Nutt., or E. 
purpurea (L.) Moench) 
5 2 
Saw palmetto (Serenoa repens (W.Bartram) Small) 6 14 
Grape seed (Vitis vinifera L.) 7 Not in top-40 
Kava-kava (Piper methysticum G.Forst.) 8 Not in top-40 
Evening primrose (Oenothera biennis L., O. lamarckiana Ser.) 9 40 
Echinacea/Goldenseal (Echinacea spp. and Hydrastis canadensis L.) 10 Not in top-40 
Cranberry (Vaccinium macrocarpon Aiton) 11 3 
Valerian (Valeriana officinalis L.) 12 16 
Source: Data extrapolated from Brevoort (1998) and Smith et al. (2018). 
 
C. Botanical Supply Chain Challenges 
While the botanical ingredients market was booming, feeding the new dietary supplement 
finished product sector, the fundamentals to support it were lacking and yet to be developed. At 
that time, quality assurance and management systems such as good agricultural and collection 
practice (GACP) guidelines and implementable standards for sustainable production, suitable for 
cultivated and/or wild-collected botanical crops, were non-existent.  
The U.S. Department of Agriculture (USDA) organic regulations, inclusive of a wild-crop 
harvesting practice standard, of particular relevance to botanicals, came into force in 2001 
(USDA 2000). Guidance on how to comply with the new wild-crop standard, however, was not 
published for another decade, in July of 2011 (USDA 2011). In the meantime, in 2006, a 
nonprofit organization, the American Herbal Products Association (AHPA) published GACPs 
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for herbal raw materials (relevant to both farmed and wild-collected botanicals), in collaboration 
with another nonprofit, the American Herbal Pharmacopoeia (AHP). As members of the AHPA 
Botanical Raw Materials Committee, authors of this paper were deeply involved with the 
development of the GACP document (AHPA 2006). 
Authoritative or official quality standards from which to establish ingredient specifications 
for testing and verifying botanical identity, composition, strength and purity, were also lacking. 
From the first publication of the Pharmacopoeia of the United States of America in 1820 (USPC 
1820) until 1920, around 875 botanical monographs were published in the USP (USPC 2016). 
including botanical drug substances and botanical preparations. However, with late nineteenth 
century advances in chemistry, the USP began to withdraw many botanical drug monographs. In 
the early twentieth century, only 170 botanical monographs remained, and by 1995, there were 
fewer than 40 USP monographs for botanicals and their preparations (Schiff et al 2006). In 1995, 
two important initiatives commenced, (1) the United States Pharmacopeial Convention (USPC) 
adopted a resolution that led to the election of a 5-year term (1995-2000) subcommittee to 
explore candidate botanicals for dietary supplement monograph development work; and (2) the 
nonprofit organization AHP was established for the express purpose of developing 
comprehensive monographs for quality control testing of botanical raw materials and extracts 
used in dietary supplement products.  
Another considerable challenge for the rapidly growing botanical supplement sector was the 
fact that many of the most popular botanical ingredients were procured, for the most part, from 
wild harvesting networks in rural and remote areas often through informal, non-documented cash 
trade lacking transparency and traceability. It wasn’t until the early 2000’s that the new USDA 
organic regulations enabled chain-of-custody and traceability of wild crops, due to the 
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documentation and mapping requirements for inspection and certification. Popular high-demand 
wild harvested botanicals at that time included (European) bilberry (Vaccinium myrtillus L.) fruit 
and leaf, black cohosh (Actaea racemosa L.) rhizome, cascara sagrada (Frangula purshiana 
Cooper) bark, (Peruvian) cat’s claw (Uncaria tomentosa (Willd. ex Schult.) DC.) bark, 
(European) dog rose (Rosa canina L.) hip, echinacea (Echinacea angustifolia DC.) root, 
(Siberian) eleuthero (Eleutherococcus senticosus (Rupr. & Maxim.) Maxim.) root, goldenseal 
(Hydrastis canadensis L.) rhizome, licorice (Glycyrrhiza glabra L., G. uralensis Fisch.) root, 
saw palmetto (Serenoa repens (W.Bartram) Small) berry, slippery elm (Ulmus rubra Muhl.) 
bark, St. John’s wort (Hypericum perforatum L.) flowering tops, and wild yam (Dioscorea 
villosa L.) rhizome, among many others. 
The conservation status of most medicinal plants had yet to be assessed, and the 
development of international standards for sustainable wild collection and ecosystem 
management were still a decade away. While the World Health Organization (WHO) 1993 
“Guidelines on the Conservation of Medicinal Plants” existed (WHO, IUCN & WWF 1993), 
which provided a framework with recommended actions, they had little impact on industry. It 
was probably not until 1996 that the industry really sat up and took notice, when the World 
Wildlife Fund-US (WWF) suggested that the U.S. Fish & Wildlife Service (USFWS) propose 
listing the popular botanical goldenseal onto Appendix II of the Convention on International 
Trade in Endangered Species (CITES) (USFWS 1996).  
And, it wasn’t until the early 2000’s, that rigorous international standards and 
corresponding guidance documents for sustainable wild collection of botanicals were being 
developed and test-implemented globally for feasibility, in collaboration with herbal companies 
(some American) and nature conservation organizations (e.g. WWF), with the financial and 
8 
 
technical support of European governmental agencies. This included the (1) German-government 
supported “International Standard for the Sustainable Wild-Collection of Medicinal and 
Aromatic Plants” (ISSC-MAP) Draft 1 (Leaman 2004), Draft 2 (Leaman & Salvador 2005), 
Working Draft (MPSG 2006), and Version 1.0 (2007) (MPSG 2007); and (2) the Swiss-
government supported “FairWild Standard,” Version 1.0 (Meinshausen et al. 2006) and Version 
2.0 (FWF 2010), the latter which incorporated the ISSC-MAP as the result of the two initiatives 
merging in October 2008 (Brinckmann 2009). 
II. Managing quality and sustainability 
When DSHEA came into being, the U.S. botanical ingredients and products sectors, for 
the most part, did not yet have the requisite standards and tools developed to cope with, not only 
exponential market growth and strains on capacity, but also a series of regulations that would 
require development and implementation of standards for quality management and sustainability 
of botanical ingredients from the field to post-harvest processing, and on to finished product 
manufacturing. This chapter will tie the thread of quality management from implementation 
GACPs and sustainable production standards in the field to GMPs in the processing facilities 
with application of pharmacopoeial quality standards in the testing laboratories as the basis of 
specifications for ensuring the proper composition, identity, purity, and strength of the botanical 
ingredient. Table 2 provides a chronology of significant post-DSHEA developments related to 
managing the quality and sustainability of botanical supplement ingredients in the U.S. 




1994, Oct. 25 
U.S. Congress “Dietary Supplement Health and Education Act of 1994” (DSHEA) becomes 
law. The Act afforded legal recognition to USP-NF standards for dietary supplement quality. 
1995, Mar. 9-12 
U.S. Pharmacopeial Convention (USPC) adopted Resolution No. 12, a resolution that 
“encouraged the USP to explore the feasibility and advisability of establishing standards and 





Nonprofit organization, the American Herbal Pharmacopoeia (AHP) is established with a 
purpose to produce comprehensive monographs that outline the quality control criteria needed 
for ensuring the identity, purity, and quality of botanical raw materials. 
1995 
Nonprofit organization, the United Plant Savers (UpS) is founded with a mission “to protect 
native medicinal plants of the United States and Canada and their native habitat while ensuring 
an abundant renewable supply of medicinal plants for generations to come.” 
1997, Sept. 18 
Goldenseal (Hydrastis canadensis) enters Appendix II of the Convention on International Trade 
in Endangered Species (CITES) as proposed by the U.S. Fish and Wildlife Service (USFWS). 
1997, Dec. 16 USDA proposes establishment of a national organic program to include wild-crop harvesting. 
1999 
The Medicinal Plant Working Group (MPWG) was established under the umbrella of the Plant 
Conservation Alliance (PCA), facilitated by the USFWS. 
2000 Nonprofit UpS publishes At-Risk and To-Watch list of native American botanicals. 
2000, Dec. 21 
USDA National Organic Program (NOP) final rule, which, of particular relevance to sustainable 
botanical supply, includes a “Wild-crop Harvesting Practice Standard” (7 CFR § 205.207). 
2004, Nov. 
Nonprofit organization, the American Herbal Products Association (AHPA) publishes 
“Background on California Proposition 65: Issues related to heavy metals and herbal products.” 
2006, Dec. 
AHPA publishes “AHPA-AHP Good Agricultural and Collection Practice for Herbal Raw 
Materials,” prepared by members of the AHPA Botanical Raw Materials Committee. 
2007, Jun. 25 
U.S. FDA final rule “Current Good Manufacturing Practice in Manufacturing, Packaging, 
Labeling, or Holding Operations for Dietary Supplements (21 CFR Part 111). 
2008, Dec. 29 USDA Forest Service final rule on “Special Forest Products and Forest Botanical Products.” 
2010, Oct. 29 
United Nations treaty affecting access & trade of medicinal plants adopted: “Nagoya Protocol 
on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from 
their Utilization to the Convention on Biological Diversity,” and came into force Oct. 12, 2014. 
2011, Jan. 4 U.S. Congress “FDA Food Safety Modernization Act” becomes law. 
2011, Jul. 22 USDA NOP issues guidance on organic “Wild Crop Harvesting.” 
2011, Nov. 2 
Three nonprofit organizations, the American Botanical Council (ABC), the AHP, and the 
University of Mississippi’s National Center for Natural Products Research (NCNPR) initiated 
the “ABC-AHP-NCNPR Botanical Adulterants Program” to educate members of the herbal and 
dietary supplement industry about ingredient and product adulteration.   
2012 
USPC published first edition of the Dietary Supplements Compendium (DSC), which brought 
together monographs and general chapters of FCC, NF and USP. 
2015, Sept. 17 
U.S. FDA final rule “Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based 
Preventive Controls for Human Food” (21CFR Part 117). 
2016, Jan. 15 
USDA NOP issues guidance on “Natural Resources and Biodiversity Conservation” for organic 
operations (farms and wild-collection operations). 
2017, March 
AHPA publishes updated “Good Agricultural and Collection Practices and Good 
Manufacturing Practices for Botanical Materials.” 
 
A. 1995-2000: AHP and USP begin to develop botanical monographs 
Due to the passage of DSHEA, the advisability of developing botanical supplement 
monographs was deliberated at the 1995 Quinquennial Meeting of the United States 
Pharmacopeial Convention (USPC). The Convention adopted a resolution to encourage USP to 
explore the feasibility and advisability of establishing standards and developing information 
concerning dietary supplements. A subcommittee on natural products was elected for a five-year 
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term (1995-2000). The subcommittee, with the assistance of an appointed advisory panel, began 
the work to select candidate botanicals for monograph and methods development (Schiff et al 
2006). Also in 1995, the nonprofit AHP was founded, and, in the meantime, has developed and 
published nearly 40 botanical monographs, possibly the most comprehensive compendium 
available providing standards for identity, analysis, and quality control. 
While the use of official pharmacopoeial standards is mandatory for quality specifications of 
botanical drugs, their use is voluntary for botanical dietary supplements in the U.S.  
“The Dietary Supplement Health and Education Act of 1994 (DSHEA) amendments to 
the Federal Food, Drug, and Cosmetic Act (FD&C Act) named the United States 
Pharmacopeia and National Formulary (USP-NF) as official compendia for dietary 
supplement ingredient quality standards. At the same time, industry compliance with 
USP-NF standards was made voluntary. Nonetheless, the amendments stipulate that if an 
herbal dietary supplement that is covered by the specifications of an official compendium 
is represented as conforming to the specifications of an official compendium, and fails to 
conform to such specifications, it shall be deemed misbranded. Thus, compliance with a 
USP monograph becomes mandatory only in cases where the product label specifies that 
it contains components with a USP quality designation” (Brinckmann 2011). 
One of the co-authors of this paper (JAB) submitted comments on FDA’s draft cGMPs 
suggesting that use of authoritative quality standards, such as those published in pharmacopoeial 
monographs, should be a required minimum basis for the establishment of botanical supplement 
ingredient specifications, in that it could be disingenuous or fraudulent for companies to market 
products with claim statements, where the evidence to support the claim is based on the use of a 
specified pharmacopoeial quality, if, in fact, the company was using inferior quality grades of 
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botanical raw materials. In the preamble of the final rule, while FDA stated that companies may 
use validated methods that can be found in official references, such as AOAC International, 
USP, and others, the agency rejected the argument that pharmacopoeial quality should be a 
minimum requirement for ingredients that are the subject of structure function claim statements 
(FDA 2007). 
In a critique of the FDA cGMPs, published in Food and Drug Law Journal, representatives 
of the USPC stated: 
“Unfortunately, these cGMPs establish no minimum requirement for quality. The 
manufacturer is entitled to use its best judgment in establishing a standard. Moreover, 
although the cGMPs will help ensure that one manufacturer’s product is similar from 
batch to batch, the specifications for similar articles can vary widely from manufacturer 
to manufacturer. Effectively, the cGMPs call for standards without standardization. A 
manufacturer may create essentially private standards for a particular dietary ingredient 
or dietary supplement, but the manufacturer need not make these standards public. One 
manufacturer’s standards may bear little or no resemblance to the standards created by 
other manufacturers for the same ingredient or product. Thus multiple manufacturers may 
establish different standards of identity, strength, quality, and purity for articles that are 
introduced into commerce under the same name” (Miller et al 2008). 
Regardless of the fact that it was not mandatory for manufacturers of supplement products to 
base their ingredient quality specifications on pharmacopoeial standards, considerable progress 
has been made over the past 25 years. Monographs relevant to specifying the quality of botanical 
supplement ingredients have been made available through the American Herbal Pharmacopoeia 
(AHP), Food Chemicals Codex (FCC), National Formulary (NF) and United States 
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Pharmacopeia (USP). Furthermore, the USPC, since 2012, publishes a separate Dietary 
Supplements Compendium (DSC), which provides monographs and general chapters of FCC, 
NF and USP along with supplemental information such as color plates and illustrations (USPC 
2019). Table 3
1
 provides a list of monographs available for botanical raw materials and extracts 
and oils obtained from them. 
B. 2000: USDA final rule for NOP (7 CFR Part 205) 
In 2000, the USDA NOP final rule was published, which, of particular relevance to 
sustainable botanical supply, included the “Wild-crop Harvesting Practice Standard” (7 CFR § 
205.207). 
Experience has shown that the implementation of sustainability standards may also 
contribute to compliance with certain aspects of FDA’s cGMPs, especially where they pertain to 
management and control of contamination. For example, the USDA NOP soil fertility and crop 
nutrient management practice standard (7 CFR §205.203) requires producers to manage plant 
and animal materials to maintain or improve soil organic matter content in a manner that does 
not contribute to contamination of crops, soil, or water by plant nutrients, pathogenic organisms, 
heavy metals, or residues of prohibited substances. Furthermore, if a botanical supplement 
component is certified organic, 7 CFR §205.670(c) requires pre-harvest or post-harvest tissue 
test sample collection to be performed by an inspector or certifying agent. 
“Sample integrity must be maintained throughout the chain of custody, and residue 
testing must be performed in an accredited laboratory. Chemical analysis must be made 
in accordance with AOAC methods or other current applicable validated methodology 
determining the presence of contaminants in agricultural products” (USDA 2000). 
                                                 
1 Due to its large size, Table 3 is presented under ANNEX I 
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C. 2006: AHPA-AHP GACPs 
The genesis of the development of GACPs, specifically designed for MAP crops (farmed and 
wild), can be traced to an initial 1983 round-table discussion at the 4th International Society for 
Horticultural Science (ISHS) Symposium in Angers, France (Máthé & Franz 1996). It would 
however be another 20 years before an elaboration of general international GACP guidelines for 
medicinal plants would be published by the World Health Organization (WHO 2003a). The 
“WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants” 
were developed in response to Resolution WHA56.31 from the Fifty-sixth World Health 
Assembly on Traditional Medicine which requested the Director-General to provide technical 
support for development of methodology to monitor or ensure product quality, efficacy and 
safety, preparation of guidelines, and promotion of exchange of information (WHO 2003b). The 
WHO GACP guidelines were primarily intended to provide “general” yet globally applicable 
technical guidance with the awareness that the GACPs would need to be adjusted according to 
each country’s actual situation. One of the main objectives of these general guidelines was to 
provide the basis for the formulation of national and/or regional GACP guidelines, species-
specific GACP monographs, and related standard operating procedures (SOPs). 
While many national and international governmental organizations have developed and 
implemented national GACPs for MAPs, for example, the China Food and Drug Administration 
(CFDA 2002), Japanese Ministry of Health, Labour and Welfare (WHO 2003a), European 
Medicines Agency (EMA) (HMPC 2006), and India’s National Medicinal Plants Board (NMPB 
2009a, 2009b), the U.S. has not yet. While GACP compliance is mandatory for botanical drugs it 
is voluntary for botanical supplements. In their 2004 guidance for industry on botanical drug 
products (FDA 2004), the FDA deferred to the EMA GACPs: 
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“Starting materials of botanical origin that are used to produce a botanical drug substance 
should be evaluated for quality. The use of appropriate starting materials and the drug 
substance manufacturer’s ability to control the source depend on appropriate 
specifications (tests, analytical procedures, and acceptance criteria). In addition to 
establishing specifications, manufacturers can achieve adequate quality control of starting 
materials by applying the principles outlined in FDA’s botanical guidance and by 
following good agricultural and good collection practice for starting materials of herbal 
origin (e.g., European Medicines Evaluation Agency HMPWP/31/99)” (FDA 2004). 
However, in the FDA’s revised botanical drug guidance (FDA 2016), the agency deferred to both 
the EMA and WHO GACPs: 
“To assess quality and therapeutic consistency, it is important to select representative raw 
material batches (i.e., raw material from three or more representative cultivation sites or 
farms) for the manufacturing of the clinical drug substance for multiple batch Phase 3 
studies. The sponsor should establish large growing regions with three or more 
cultivation sites or farms whose locations are purposefully selected to be representative of 
the regions for each of the botanical raw materials following the principles of Good 
Agricultural and Collection Practices (GACP).” [Note: FDA footnotes this statement with 
“See the World Health Organization’s “WHO guidelines on good agricultural and 
collection practices (GACP) for medicinal plants” and the European Medicines Agency’s 
“Guideline on Good Agricultural and Collection Practice (GACP) for Starting Materials 
of Herbal Origin”]” (FDA 2016). 
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And, while the USPC has, in the past, proposed to develop a new General Chapter section on 
GACPs, USP General Chapter <2030> “Supplemental Information for Articles of Botanical 
Origin” provides general guidance deferring to the WHO GACP: 
“It is recommended that, at a minimum, growers and others involved in the handling and 
distribution of botanical products should become familiar with and follow the WHO 
Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants” 
(USPC 2018a). 
Thus, for the U.S. context of quality management of botanical crops, in lieu of official 
GACPs from either the FDA or USP, two nonprofit organizations, AHPA and AHP collaborated 
in the production of the “AHPA-AHP Good Agricultural and Collection Practice for Herbal Raw 
Materials,” initiated under the auspices of the AHPA Botanical Raw Materials Committee 
(AHPA 2006). While it has no legal standing in the U.S., AHPA states that its GACP has 
relevance to herbal raw materials used in all herbal products, including cosmetics, dietary 
supplements, drugs, and foods. However, it should also be noted that the Canadian government 
officially recognized the AHPA-AHP GACP in their “Quality of Natural Health Products 
Guide” as acceptable for botanical medicinal ingredients of licensed natural health products in 
Canada (NNHPD 2015). 
D. 2007: U.S. FDA final rule cGMPs (21 CFR Part 111) 
FDA’s 2007 final rule on cGMP in manufacturing, packaging, labeling, or holding operations 
for dietary supplements (21 CFR Part 111) required the establishment of quality specifications 
with scientifically valid methods for ensuring the composition, identity, purity and strength of 
dietary supplement components, as well as the establishment of limits on types of contamination 
that may adulterate or may lead to adulteration (FDA 2007). Experience of some companies has 
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shown that compliance with the cGMP can be accomplished by implementing other standards 
earlier in the botanical supply chain. For example, GACP compliance generally requires written 
agreements between producers and buyers of botanicals with regard to quality such as content of 
active principle, macroscopical and olfactory properties, limit values for microbial 
contamination, chemical residues and heavy metals, and that specifications should be based on 
recognized national pharmacopoeial monographs (HMPC 2006). And, basing one’s quality 
specification on quality standards monographs such as those of the USP ensure that scientifically 
valid methods and limits will be established for determining composition, identity, purity, and 
strength. 
Subsequently, in 2011, also impacting the production and trade of botanical dietary 
supplement ingredients, Congress enacted the Food Safety Modernization Act (FSMA) 
“in response to dramatic changes in the global food system and in our understanding of 
foodborne illness and its consequences, including the realization that preventable 
foodborne illness is both a significant public health problem and a threat to the economic 
well-being of the food system. FSMA is transforming the nation’s food safety system by 
shifting the focus from responding to foodborne illness to preventing it” (FDA 2018b). 
As part of the FSMA, Congress has enacted several rules: 
 Preventive Controls for Human Food 
 Foreign Supplier Verification Program for Importers of Food for Human and Animals 
 Sanitary Transportation of Human and Animal Food 
 Mitigation Strategies to Protect Food against Intentional Adulteration 
 Accredited Third Party Certification 
 Preventive Controls for Food for Animals 
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 Standards for Produce Safety 
While these rules are now final, all corresponding guidance documents are not yet finalized. 
III. Control of adulterants and contaminants 
This section discusses the problems and solutions concerning adulteration of botanical 
ingredients, whether intentional (economic) or unintentional (look-alike species growing in 
proximity to target species). Additionally unavoidable contamination of botanical ingredients has 
become one of the most disruptive quality problems negatively impacting trade and quality of 
products. Our planet is not getting cleaner. Anthropogenic pollution and related contamination to 
the natural environment is now global and pervasive. Types of pollution affecting botanical 
crops, whether farmed or wild-collected, include heavy metals contamination from industrial 
pollution, nonpoint source pesticide pollution from conventional agriculture operations 
negatively impacting certified organic crops and wild crops, pharmaceutical drugs in irrigation 
water, plastic pollution, polycyclic aromatic hydrocarbons (PAHs), and radioactive residues. 
i. Economic adulteration 
In 2011, three nonprofit organizations, the ABC, the AHP, and the University of 
Mississippi’s National Center for Natural Products Research (NCNPR) initiated the “ABC-AHP-
NCNPR Botanical Adulterants Program” to educate members of the herbal and dietary 
supplement industry about ingredient and product adulteration.  To date, seventeen 
comprehensive Botanical Adulterant Bulletins have been published and seven laboratory 
guidance documents (Table 4), among other materials useful for the industry 
Table 4: Botanical Adulterants Program bulletins and laboratory guidance documents list 
Date Title 
2015, January Skullcap Adulteration Laboratory Guidance Document 
2015, August Bilberry Fruit Extract Laboratory Guidance Document 
2015, November Black Cohosh Adulteration Laboratory Guidance Document 
2016, April Adulteration of Bilberry (Vaccinium myrtillus) Extracts 




2016, April Adulteration of Skullcap (Scutellaria lateriflora) 
2016, June Adulteration of Black Cohosh (Actaea racemosa) 
2016, June Adulteration of Hydrastis canadensis root and rhizome 
2016, August Adulteration of Arnica (Arnica montana) 
2017, January St. John's Wort (Hypericum perforatum) Adulteration 
2017. March Adulteration of Grapefruit Seed Extract (Citrus paradisi) 
2017, May Grapefruit Seed Extract Laboratory Guidance Document 
2017. August Tea Tree (Melaleuca alternifolia and M. linariifolia) Oil 
2017, October Adulteration of Rhodiola (Rhodiola rosea) Rhizome, Root, and Extracts 
2017, December Adulteration of Cranberry (Vaccinium macrocarpon) 
2018, January Adulteration of Ginkgo biloba Leaf Extract 
2018, April Pomegranate Products Laboratory Guidance Document 
2018, May Turmeric (Curcuma longa) Root and Rhizome, and Root and Rhizome Extracts 
2018, June Boswellia serrata Adulteration 
2018, September Adulteration of Maca (Lepidium meyenii) 
2018, September Tea Tree Oil Laboratory Guidance Document 
2018, October Adulteration of Saw Palmetto (Serenoa repens) 
2018, November Cranberry Products Laboratory Guidance Document 
2019, January Adulteration of Ashwagandha (Withania somnifera) Roots, and Extracts 
2019, February Grape Seed Extract Laboratory Guidance Document 
SOURCE: American Botanical Council: http://cms.herbalgram.org/BAP/  
ii. Heavy metal pollutants in the environment 
Medicinal plant crops can be contaminated by absorbing heavy metals from soil, water and 
air, i.e. from industrial emissions, mining, smelting, landfills, conventional agriculture (fertilizers 
and pesticides; polluted water used for irrigation, sewage sludge), transportation (traffic-induced 
contaminated atmosphere), rainfall, and atmospheric dust: 
 Air: Aerial plant parts accumulate heavy metals by uptake of airborne pollution relative 
to proximity to industrial zones and traffic (Serbula et al. 2013). 
 Soil: “Absorption of heavy metal in medicinal plants is governed by soil characteristics 
such as pH, salinity, conductivity and organic matter content” (Rădulescu et al. 2013). 
 Water: “Toxic elements from wastewater may contaminate agricultural soils, water 
supplies and environment… Elevated levels of heavy metals in plants are reported from 
the areas having long-term uses of treated or untreated wastewater” (Shaban et al. 2016).  
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While the United States Pharmacopoeia (USP) prescribes general limits for elemental 
impurities in general chapter 561  ARTICLES OF BOTANICAL ORIGIN (USPC 2018b) [see 
Table 5], the State of California enacted its own limits through implementation of the Safe 
Drinking Water and Toxic Enforcement Act of 1986, more commonly known as California 
Proposition 65. 
Table 5: USP General Chapter 561  Articles of Botanical Origin - Limits of Elemental Impurities 
Element Limit (µg/g) 
Arsenic (inorganic) 2 
Cadmium 0.5 
Lead 5 
Mercury (total) 1 
Methylmercury (as Hg) 0.2 
 
The California Proposition 65 limits for heavy metals continue to impact the botanical 
dietary supplement trade, from increased testing for selection of California-compliant lots, to 
product brands lowering their daily serving size instructions on labeling in order to comply. That 
is, because the limits are not based on content but on daily ingestion levels. For example, the 
California maximum allowable daily level (MADL) for lead content in an herbal dietary 
supplement product is not-more-than 0.5 µg per day. Depending on the recommended daily 
serving size for a product, the USP limit of 5 µg per gram (in botanical material) may, or may 
not, prove to be compliant in California. In 2004, the American Herbal Products Association 
(AHPA) published its “Background on California Proposition 65: Issues related to heavy metals 
and herbal products,” (McGuffin & Norris 2004), which was revised in 2008, and in 2010, and 
again in 2017, retitled as “Guidance on California Proposition 65 and Herbal Products” (AHPA 
2017). AHPA’s document provides guidance for industry on regulatory and liability implications 




iii. Nonpoint source pesticide contamination 
In the decades since the passage of DSHEA, pesticide drift from conventional agriculture 
sites has become ubiquitous in the natural world. Residues can now be detected the world over, 
in the air, ice, snow, soil and water, and on crops grown without the intentional use of pesticides. 
 Residues of “legacy” (e.g. DDT) and “current use pesticides” (CUPs) are now detected in 
Arctic ice caps (evidence of long range atmospheric transport). 
 In rural and remote areas, there is widespread contamination of wildflowers and bee-
collected pollen with agricultural pesticides. 
 Nonpoint source pesticide detection is an increasing problem even with certified 
organically grown and/or wild-collected botanicals, where pesticides have not been 
applied. 
As per FDA’s 21 CFR Part 111 cGMPs for dietary supplements, specifications are required 
to ensure that a dietary supplement derived from a botanical source does not contain 
contaminants such as an unlawful pesticide. Pesticide tolerances, however, are established by the 
Environmental Protection Agency (EPA) on a crop-specific and/or crop-group basis. While FDA 
enforces the EPA limits that were established mainly for food crops, tolerances have been 
established for only a relatively small number of botanical crops such as certain aromatic or 
culinary herbs that are grown in the U.S. on a large scale, e.g., spearmint (Mentha spicata) and 
hops (Humulus lupulus). EPA tolerances have not been established for thousands of other 
botanicals in commerce. Thus, when de minimis levels of pesticide residues are found at above 
the limit of quantitation (LoQ), even on wild-collected botanicals or on certified organically 
grown botanicals, where no pesticides were intentionally applied, there is a risk of FDA 
detention or import refusal at the port of entry. 
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Although USP General Chapter 561  Articles of Botanical Origin provides reasonable limits 
for pesticide residues, in the U.S. the USP limits are applicable only to botanical drugs and not to 
botanical dietary supplements. That is because dietary supplements are regulated as a subset of 
foods. EPA establishes limits for food crops while USP has the authority to establish limits for 
botanical drug crops.  
In 2016, a stimuli article titled “Need for Clear Regulation of Pesticide Residue Limits for 
Articles of Botanical Origin,” was published in the Pharmacopeial Forum for public comment 
(USP Botanical Dietary Supplements and Herbal Medicines Expert Committee 2016). This was 
followed-up with a USP roundtable on pesticide residues in botanical dietary supplements with 
participants from governmental agencies, trade associations, and industry.  
IV. Conservation and Sustainability 
This chapter looks at impacts of international conventions such as the Convention on 
Biological Diversity (CBD) and the Convention on International Trade in Endangered Species 
(CITES) on botanical ingredient production and import trade, as well as conservation status 
assessments of botanical species carried out by non-governmental organizations such as IUCN 
Red List assessments, and the emergence of voluntary standards for demonstrating economic, 
environmental and social sustainability in the botanical supply chain.  
By the start of the 21
st
 century, awareness grew in the global botanical trade that conserving 
biodiversity and improving rural economies appeared to be linked to access to traditional 
harvesting areas, sustainable production, trade and use of ever-increasing quantities of botanicals 
needed for the natural cosmetic, dietary supplement, botanical drug, and functional food sectors. 
This was evidenced by the fact that numerous sustainability standards (both national and private 
voluntary) as well as GACP standards designed for MAP crop production were being developed 
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through multi-stakeholder processes and implemented with funding support from governmental 
agencies (e.g. German Federal Agency for Nature Conservation (BfN)), intergovernmental 
organizations (e.g. agencies of the United Nations), and non-governmental organizations (e.g. 
WWF). 
“Implementation of voluntary sustainability standards (VSS) that include economic, 
environmental and social criteria and indicators is an emerging market-based approach to 
biodiversity conservation, sustainable harvesting and commercial use of MAPs, and to 
demonstrate compliance with international agreements. While such standards are 
voluntary, in that compliance is not required by governmental regulations, independent 
third-party inspection and certification organisations determine if companies are 
operating in compliance with the standard” (Brinckmann 2017; Komives & Jackson 
2014). 
From 2010 to 2014, international botanical ingredient and finished product companies also 
needed to learn the (new) ropes for compliance with a United Nations multilateral treaty, adopted 
in 2010 for enforcement by 2014, the “Nagoya Protocol on Access to Genetic Resources and the 
Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on 
Biological Diversity” (Secretariat of the Convention on Biological Diversity 2011). Some of the 
aforementioned voluntary sustainability standards provide ways for companies to demonstrate 
compliance with the access and benefit sharing (ABS) requirements of the protocol, for example, 
the Ethical BioTrade Standard, developed by the Union for Ethical BioTrade (UEBT), and the 
FairWild Standard (FWS), developed by the FairWild Foundation. Criterion 4.2 of the FWS 
requires that agreements made with local communities and/or indigenous peoples are executed in 
compliance with relevant international and national laws and ABS regulations including 
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protection of traditional knowledge (FWF 2010). Written and mutually accepted fair and 
equitable agreements on use of medicinal plants and associated traditional knowledge must be in 
place to maintain FairWild certification (FWF 2013). Section 3 of the Ethical BioTrade Standard 
“Fair and Equitable Sharing of Benefits derived from the Use of Biodiversity” includes 
comparable requirements (UEBT 2012). 
Table 6 provides a listing of selected botanicals with information on their conservation status, 
for example if the species is listed in the CITES appendixes, or has been assessed according to 
the IUCN Red List criteria or the UpS ranking tool. Species prioritized in the AHPA tonnage 
survey are also included in the table if the species has been assessed according to UpS, IUCN or 
CITES. 
Table 6: Conservation status of selected botanicals used in botanical supplement products 
Botanical name CITES IUCN Red List UpS 
Agarwood (Aquilaria spp.) II 
CR, Aquilaria crassna; CR,  A. 
malaccensis; VU, A. sinensis 
 
American ginseng (Panax quinquefolius L.) II Not assessed ATR 
Asian ginseng (Panax ginseng C.A.Mey.) from Russia II Not assessed  
Arnica (Arnica spp.)  LC, Arnica montana TW 
Bethroot (Trillium erectum L.)  Not assessed ATR 
Bletilla (Bletilla striata (Thunb.) Rchb.f.) II Not assessed  
Bloodroot (Sanguinaria canadensis L.)  Not assessed ATR 
Black cohosh (Actaea racemosa L.)  Not assessed ATR 
Blue cohosh (Caulophyllum thalictroides (L.) Michx.)  Not assessed ATR 
Brazilian rosewood (Aniba rosaeodora Ducke) II EN  
Candelilla (Euphorbia antisyphilitica Zucc.) II No assessed  
Cape aloe (Aloe ferox Mill.) II Not assessed  
Cascara sagrada (Frangula purshiana Cooper)  LC TW 
Chun lan (Cymbidium goeringii (Rchb.f.) Rchb.f.) II Not assessed  
Common pleione (Pleione yunnanensis (Rolfe) Rolfe) II Not assessed  
Costus (Saussurea costus (Falc.) Lipsch.) I CR  
Dendrobium (Dendrobium spp.) II 
CR, D. huoshanense; CR, D. 
officinale;  
 
Desert broomrape (Cistanche deserticola Y.C.Ma) II Not assessed  
Echinacea (Echinacea spp.)  Not assessed ATR 
Elephant tree (Bursera microphylla A.Gray)  Not assessed TW 
Eyebright (Euphrasia spp.)  Not assessed ATR 
Fragrant rosewood (Dalbergia odorifera T.C.Chen) II VU  
False unicorn (Chamaelirium luteum (L.) A.Gray)  Not assessed ATR 
Gastrodia (Gastrodia elata Blume) II VU  
Gentian (Gentiana spp.)  CR, G. kurroo TW 
Goldenseal (Hydrastis canadensis L.) II VU ATR 
Goldthread (Coptis spp.)  EN, C. teeta TW 
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Botanical name CITES IUCN Red List UpS 
Guaiacum (Guaiacum spp.) II EN, G. officinale; NT, G. sanctum  
Hoodia (Hoodia gordonii (Masson) Sweet ex Decne.) II Not assessed  
Indian rosewood (Dalbergia sissoo DC.) II Not assessed  
Jatamansi (Nardostachys grandiflora DC.) II CR  
Jivakah (Malaxis acuminata D.Don) II Not assessed  
Lady’s slipper orchid (Cypripedium spp.) II LC, C. acaule; LC, C. parviflorum ATR 
Lobelia (Lobelia spp.)  LC, L. cardinalis; LC, L. siphilitica TW 
Lomatium (Lomatium dissectum (Nutt.) Mathias & 
Constance) 
 Not assessed ATR 
Oregon grape (Mahonia aquifolium (Pursh) Nutt., M. 
nervosa (Pursh) Nutt., M. repens (Lindl.) G. Don)) 
 Not assessed TW 
Osha (Ligusticum porteri J.M.Coult. & Rose, L. spp.)  Not assessed ATR 
Partridge berry (Mitchella repens L.)  Not assessed TW 
Perry’s aloe (Aloe perryi Baker) II NT  
Picrorhiza (Picrorhiza kurrooa Royle) II Not assessed  
Pleurisy (Asclepias tuberosa L.)  Not assessed TW 
Pygeum (Prunus africana (Hook.f.) Kalkman) II VU  
Red saunders (Pterocarpus santalinus L.f.) II NT  
Riddhi (Habenaria intermedia D.Don) II Not assessed  
Sandalwood (Santalum spp.)  VU, S. album ATR 
Scythian lamb (Cibotium barometz (L.) J.Sm.) II Not assessed  
Skullcap (Scutellaria lateriflora L.)  LC  
Slippery elm (Ulmus rubra Muhl.)  LC ATR 
Sundew (Drosera spp.)  Not assessed ATR 
True unicorn (Aletris farinosa L.)  Not assessed ATR 
Venus’ fly trap (Dionaea muscipula J.Ellis)  VU ATR 
Wild cherry (Prunus serotine Ehrh.)  LC  
Wild indigo (Baptisia tinctoria (L.) Vent.)  Not assessed TW 
Wild yam (Dioscorea villosa L., D. spp.)  Not assessed ATR 
Witch hazel (Hamamelis virginiana L.)  LC  
Yerba mansa (Anemopsis californica (Nutt.) Hook. & 
Arn.) 
 Not assessed TW 
Legend:  
CITES Appendices: Appendix I: lists species that are the most endangered; threatened with extinction. CITES prohibits 
international trade in specimens of these species except when the purpose of the import is not commercial, for instance for 
scientific research. Appendix II: lists species that are not necessarily now threatened with extinction but that may become so 
unless trade is closely controlled. It also includes so-called "look-alike species", i.e. species whose specimens in trade look like 
those of species listed for conservation reasons. Appendix III: is a list of species included at the request of a Party that already 
regulates trade in the species and that needs the cooperation of other countries to prevent unsustainable or illegal exploitation. 
IUCN Categories: CR, critically endangered; DD, data deficient; EN, endangered; LC, least concern; NT, near threatened; VU, 
vulnerable. 
UpS Ranking: ATR, at-risk; TW, to watch. 
 
A. AHPA tonnage survey  
The American Herbal Products Association (AHPA) initiated and has conducted “Tonnage 
Surveys” since 1999 for the purpose of quantifying the annual harvests of specific North 
American botanicals in commerce. AHPA's Tonnage Survey is considered "a vital index of 
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native U.S. botanical consumption," according to the Fish and Wildlife Service of the U.S. 
Department of the Interior. According to AHPA: 
“Harvest information is a more powerful tool when harvest amounts are tabulated to 
include combined total usage. By working together, AHPA and the herbal products 
industry generate valuable information that helps ensure sustainable growth and stability. 
Participation in this survey also demonstrates the industry's commitment to sustainable 
harvests” (AHPA 2019). 
The first of these surveys addressed only the plant goldenseal (Hydrastis canadensis) and 
solicited information about both wild and cultivated harvests for 1998, as well as certain harvest 
and cultivation practices. The second survey extended this attention on goldenseal for the 1999 
harvest year and also compiled information for the years 1997–1999 for a number of other 
plants. The 2000–2001 survey identified all of the plants from these earlier efforts and a number 
of additional species. These surveys have continued to evolve by adding new species, more 
cultivation oriented, fresh and dried material numbers and other information based on the need of 
new data for today’s market. Figure 1 provides a chart illustrating the annual harvested quantities 




Fig. 1 Annual harvested quantities (dry weight basis) of four high-volume botanicals, 1999-2010, excerpted with permission 
from the “Tonnage Surveys of Select North American Wild-Harvested Plants, 2006–2010” (AHPA 2012). 
 
According to AHPA, with regard to its 14 years of harvest data for goldenseal: 
“Annual variations in harvest quantities for certain of these commodities are consistent with 
market factors over the past several years. This review of data over the fourteen-year period 
reveals that patterns in market demand are reflected in annual variations of harvests of both 
wild and cultivated sources of these botanical commodities. Several species for which there 
are large market demands are cultivated to a sufficient degree so that some meaningful 
portion of the total usage is provided by farmers rather than by harvesters of wild plants. The 
most recent surveys affirm that this continues to be the case for the goldenseal market… 
“However, market demand, not plant availability, seems to be the primary driver of total 
harvest quantities. As has been noted in other publications, information about the population 
dynamics of many of these species in their native habitats is not well understood” (AHPA 
2012). 
The latest survey (with submission deadline of 26 April 2019), continues to focus on selected 
North American botanicals that are produced in part from wild-harvested populations, but has 
been expanded to track 51 herbal commodities representing 44 species, including American 
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ginseng, black cohosh, cascara sagrada, Echinacea spp., saw palmetto, slippery elm, and witch 
hazel (AHPA 2019). 
Data from the AHPA tonnage surveys are the foundational information needed to both track and 
assess the sustainability of harvests of North American species in trade within the herbal dietary 
supplement and herbal medicine industries. It may still require a collaborative effort between 
industry, regulatory and nature conservation organizations to objectively and impartially study the 
data thoroughly enough to better understand the impact on native species relative to each species’ life 
cycle, while considering other impacts such as human expansion and habitat depletion.  
B. Medicinal Plant Working Group 
Facilitated by the USFWS, the Medicinal Plant Working Group (MPWG) formed in 1999: 
“Recognizing that commercial demands may pose threats to native plants in the United States, 
representatives from industry, government, academia, tribes, and environmental organizations 
joined together to form the Medicinal Plant Working Group (PCA-MPWG) under the umbrella 
of the Plant Conservation Alliance (PCA)” (Lyke 2000). The primary focus of the MPWG has 
been to facilitate action in cases where the conservation status of a native medicinal plant is of 
concern. 
C. UpS ranking tool 
While UpS launched their medicinal plant species “At Risk” and “To Watch” lists in 2000, it 
was initially informed by input from UpS-member herbalists, ecologists, growers, and buyers. As 
the botanical industry continued to grow rapidly, UpS realized that a more transparent 
methodology was needed. As the result of a multi-year, multi-stakeholder process, in 2014, UpS 
launched what it called a “Ranking Tool Created for Medicinal Plants.” The tool can be used to 
quantify and compare vulnerability to overharvest for wild collected medicinal plants, scoring 
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species “according to their life history, the effects of harvest, their abundance and range, habitat, 
and demand” (Castle et al. 2014). 
D. USDA NOP biodiversity conservation guidance 
The general natural resources and biodiversity conservation requirement of the USDA 
organic regulations (7 CFR §205.200) requires producers (both farms and wild collection 
operations) to “maintain or improve the natural resources of the operation, including soil and 
water quality.” And the wild-crop harvesting practice standard (7 CFR §205.207) states that a 
“wild crop must be harvested in a manner that ensures that such harvesting or gathering will not 
be destructive to the environment and will sustain the growth and production of the wild crop” 
(USDA 2000). In 2011, USDA published guidance aiming to clarify the ways in which certified 
operations could demonstrate compliance with the standard (USDA 2011). Then, 16 years after 
the organic regulations came into force, guidance was finally published on the biodiversity 
conservation requirements of organic operations (USDA 2016a). In response to public 
comments, USDA stated: 
“There are many ways for operations to meet the requirements of § 205.200… Wild 
harvest operations may voluntarily elect to follow the FairWild Foundation (FWF) 
standards in order to meet the NOP requirements for biodiversity conservation; however 
the change was not made to the final guidance” (USDA 2016b). 
E. Emergence of voluntary sustainability standards 
The end of the 20
th
 century saw the emergence of voluntary sustainability standards (VSS) 
relevant to the production and trade of medicinal and aromatic plants according to principles of 
economic, environmental, and social sustainability. For example, Fair Trade International (FLO) 
was founded in 1997 in Bonn, Germany, and soon afterwards developed fair trade standards for 
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herbs, herbal teas, and spices. In 2000, the USDA National Organic Program (NOP) standards 
were published. In the first two decades of the 21
st
 century, there has been a proliferation of VSS, 
with several hundreds of botanical species being traded globally with one or more certifications. 
Table 7 provides a list of selected VSS that are being applied to botanical crops. Implementation 
of VSS by botanical producers can, not only fill in some of the gaps in GACP guidelines and 
organic agriculture regulations, respectively, but also provide producers with the value-addition 
of certifications that demonstrate compliance with credible sustainability standards, that can 
strengthen their economic viability and market position (Brinckmann 2016). 
Table 7: Selected voluntary sustainability standards applicable to botanical crops 







Agricultural Production Standard Fair Trade USA (FTUSA) ✔ ✔ ✔ 
Biodynamic® Farm Standard DEMETER Association Inc.  ✔  
EcoSocial Fair 
Instituto Biodinâmico de 
Desenvolvimento Rural (IBD) 
✔ ✔ ✔ 
Ethical BioTrade Standard 
Union for Ethical BioTrade 
(UEBT) 
✔ ✔ ✔ 
Fair Choice Social and Fair Trade 
Standard 
CONTROL UNION (CU) ✔ ✔ ✔ 
Fair For Life Standard ECOCERT SA ✔ ✔ ✔ 
Fairtrade Standard for Herbs, Herbal 
Teas & Spices for Small Producer 
Organizations and traders 
Fairtrade Labelling Organizations 
International, e.V. (FLO) 
✔  ✔ 
Fairtrade Standard for Herbs and 
Herbal Teas for Hired Labour and 
Traders 
Fairtrade Labelling Organizations 
International, e.V. (FLO) 
✔  ✔ 
FairTSA Consolidated standards for 
the production of agricultural 
products, processed foods, wild 
collected plants, handicrafts and 
personal-care products 
Fair Trade Sustainability Alliance 
(FairTSA) 
✔ ✔ ✔ 
FairWild Standard FairWild Foundation (FWF) ✔ ✔ ✔ 
National Standard for Organic 
Production 
United States Department of 
Agriculture (USDA) 
 ✔  
Non-GMO Project Standard Non-GMO Project  ✔  
Regenerative Organic Certification 
Standard 
Regenerative Organic Alliance ✔ ✔ ✔ 
Sustainable Agriculture Standard Rainforest Alliance and UTZ  ✔  
UEBT-UTZ Sustainable Herbal Tea 
Standards 
UEBT and UTZ ✔ ✔ ✔ 
SOURCE: Table created by J.A. Brinckmann for the AHPA Sustainability Sub-committee. 
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V. Conclusion and Recommendations for the future 
This paper shows that, twenty-five years since DSHEA, in response to strains caused by a 
continually growing market demand for botanical ingredients and products in the United States, a 
considerable range of useful standards, guidance manuals, and tools have been developed by 
educational organizations (e.g. ABC-AHP-NCNPR), governmental organizations (e.g. FDA, 
USDA-NOP), medicinal plant conservation organizations (e.g. IUCN-MPSG, PCA-MPWG, 
UpS), quality standards setting organizations (e.g. AHP, USP), sustainability standards setting 
organizations (e.g. FLO, FWF, UEBT), and trade associations (e.g. AHPA). While compliance 
with FDA regulations governing the manufacture and marketing of herbal dietary supplement 
products is mandatory, the use of pharmacopoeial quality standards, GACP standards, and 
sustainability standards (all of which support regulatory compliance), is voluntary.  
The way that botanical ingredients and products are regulated and marketed in the United 
States, for the most part, remains unique and possibly an anomaly in the world, certainly by 
comparison to the frameworks of our neighbors and trading partners, such as Canada, Mexico, 
the European Union, Australia, Japan, and China. In the aforementioned countries, the same 
types of ingredients are generally viewed today as active ingredients for use in licensed, listed, or 
registered medicinal products that require pre-marketing authorization. This means that 
implementation of suitable GACPs is expected for quality assurance of active ingredients and 
use of pharmacopoeial monographs, to serve as the basis for quality specifications, is mandated. 
In the United States, GACP implementation and compliance with pharmacopoeial quality 
standards is mandatory only for botanical drugs but voluntary for botanical dietary supplements. 
This difference leaves it up to the individual company whether, or not, they will make such 
commitments to quality that will increase the price of their finished products. It is difficult for 
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the consumer in the United States to understand and sort out quality differences between 
similarly packaged dietary supplement products (and just about every company claims that they 
have the highest quality!). 
Commitments to nature conservation, sustainable production and trade is a different 
matter and perhaps easier for American companies to communicate. For example, in the 
European Union, registered herbal medicinal products are not permitted to carry any certification 
logos on the retail packages. That is because of EU medicines policy stating that the conservation 
and sustainability status of medicinal ingredients and products have nothing to do with 
pharmaceutical quality or safety and efficacy of the medicine. That is an unfortunate policy (for 
European consumers concerned with ethical trade and sustainability). However, in the United 
States, it is not unusual to find herbal dietary supplement products with multiple credible 
certification marks on the labeling, demonstrating to the consumer that the product and its 
ingredients conform to a range of environmental, economic, and social sustainability standards.  
Regardless of market trends and consumer preferences, companies intrinsically 
concerned with reproducible quality, safety and efficacy of their botanical products may need to 
engage more deeply in the ecological-economic viability of the rural and remote communities 
where so many medicinal plants are produced. With mass migration of youth to urban areas, 
happening at a scale never before seen in the world, labor is rapidly disappearing in rural farming 
and wild-collection regions. Non-sustainable rural livelihoods can lead to land-use changes, loss 
of ecosystem stewardship and biodiversity. The rapid loss of biodiversity in recent decades, not 
only impacts access to and quality of wild botanicals, but is reportedly an existential threat 
(IPBES 2019). There may be a correlation between sustainable resource management and 
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equitable trade, with a companies’ ability to procure increasing quantities of botanicals of a 
specified and consistent quality.  
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ANNEX I: Table 3: Botanical, algal, fungal quality standards monographs available 
from AHP, FCC, NF, USP 
 
Table 3: Botanical, algal, fungal quality standards monographs available from AHP, FCC, NF, and USP 
Monograph AHP FCC NF USP 
Acacia (Gum Arabic)  X X  
Acacia Syrup   X  
Agar  X X  
Aloe (Dried Latex)    X 
Aloe Vera Leaf, Leaf Juice & Inner Leaf Juice X    
Ambrette Seed Oil  X   
American Ginseng Root X   X 
American Ginseng Root Dry Extract    X 
Amla Fruit X    
Amyris Oil, West Indian Type  X   
Andrographis (Leaf and Stem)    X 
Andrographis Dry Extract    X 
Angelica Root Oil  X   
Angelica Seed Oil  X   
Anise Oil  X X  
Annatto Extracts  X   
ARA from Fungal (Mortierella alpina) Oil  X   
Arabinogalactan  X   
Astaxanthin Esters (from Haematococcus pluvialis)  X  X 
Ashwagandha Root X   X 
Ashwagandha Root Dry Extract    X 
Asian Ginseng Root    X 
Asian Ginseng Root Dry Extract    X 
Astragalus Root X   X 
Astragalus Root Dry Extract    X 
Aztec Marigold Zeaxanthin Extract    X 
Bacopa (Leaf and Stem)    X 
Bacopa Dry Extract    X 
Balsam Peru Oil, Cold-pressed  X   
Banaba Leaf    X 
Banaba Leaf Dry Extract    X 
Basil Oil, Comoros Type  X   
Basil Oil, European Type  X   
Bay Oil  X   
Belleric Myrobalan Fruit X    
Bergamot Oil, Cold-pressed  X   
Bilberry Fruit X    
Bilberry Fruit Dry Extract    X 
Birch Tar Oil, Rectified  X   
Black Cohosh (Rhizome) X   X 
Black Cohosh Dry Extract    X 
Black Cohosh Fluidextract    X 
Black Haw Bark X    
Black Pepper (Fruit)    X 
Black Pepper Dry Extract    X 
Black Pepper Oil  X   
Blue Cohosh Root / Rhizome X    
Bois de Rose Oil  X   
Borage Seed Oil    X 
Boswellia serrata (Oleogum Resin)    X 
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Monograph AHP FCC NF USP 
Boswellia serrata Extract     
Cananga Oil  X   
Candelilla Wax  X X  
Cannabis Inflorescence X    
Capsicum (Ripe Fruit)    X 
Capsicum Oleoresin    X 
Capsicum Tincture    X 
Caraway Fruit   X  
Caraway Oil  X X  
Cardamom Seed   X  
Cardamom Oil  X X  
Cardamom Tincture, Compound   X  
Carnauba Wax  X X  
Carrageenan  X X  
Carrot Seed Oil  X   
Casanthranol    X 
Cascara Fluidextract, Aromatic    X 
Cascara Sagrada (Aged Bark)    X 
Cascara Sagrada Dry Extract    X 
Cascara Sagrada Fluidextract    X 
Cascarilla Oil  X   
Cassia Oil  X   
Castor Oil  X  X 
Castor Oil, Aromatic    X 
Castor Oil Emulsion    X 
Cat’s Claw (Stem Inner Bark)    X 
Cat’s Claw Dry Extract    X 
Cedar Leaf Oil  X   
Celery Seed Oil  X   
Centella asiatica (Aerial Parts)    X 
Centella asiatica Dry Extract    X 
Centella asiatica Triterpenes    X 
Chamomile (Flower Heads)    X 
Chamomile Oil, English Type  X   
Chamomile Oil, German Type  X   
Chaste Tree Fruit X   X 
Chaste Tree Fruit Dry Extract    X 
Chebulic Myrobalan Fruit X    
Cherry Juice   X  
Cherry Syrup   X  
Chia Seed Oil    X 
Chinese Salvia (Root and Rhizome)    X 
Chocolate   X  
Chocolate Syrup   X  
Cinnamomum cassia Twig    X 
Cinnamon Bark Oil, Ceylon Type  X   
Cinnamon Leaf Oil  X   
Clary Oil  X   
Clove Flower Bud Oil  X X  
Clove Leaf Oil  X   
Clove Stem Oil  X   
Cocoa Butter   X  
Coconut  Oil (Refined)   X  
Coconut Oil (Unhydrogenated)  X   
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Monograph AHP FCC NF USP 
Coffee Fruit Dry Extract    X 
Cognac Oil, Green  X   
Coix Seed    X 
Copaiba Oil  X   
Coriander Oil  X X  
Costus Root Oil  X   
Cramp Bark X    
Cranberry Fruit X    
Cranberry Liquid Preparation    X 
Crypthecodinium cohnii Oil    X 
Cubeb Oil  X   
Cumin Oil  X   
Curcuminoids    X 
Dammar Gum  X   
Dang Gui Root X    
Dill Seed Oil, European Type  X   
Dill Seed Oil, Indian Type  X   
Dillweed Oil, American Type  X   
Echinacea angustifolia Root X   X 
Echinacea angustifolia Dry Extract    X 
Echinacea pallida Root X   X 
Echinacea pallida Dry Extract    X 
Echinacea purpurea Aerial Parts X   X 
Echinacea purpurea Dry Extract    X 
Echinacea purpurea Root X   X 
Eleuthero Root and Rhizome    X 
Eleuthero Root and Rhizome Dry Extract    X 
Eucalyptus Oil  X X  
European Elder Berry Dry Extract    X 
Evening Primrose Oil    X 
Fennel Oil  X X  
Fenugreek Seed    X 
Fenugreek Seed Dry Extract    X 
Feverfew Aerial Parts X    
Feverfew Leaf    X 
Fir Needle Oil, Canadian Type  X   
Fir Needle Oil, Siberian Type  X   
Flax Seed Oil    X 
Forskohlii (Root)    X 
Forskohlii Dry Extract    X 
Galageenan   X  
Ganoderma lucidum Fruiting Body    X 
Garcinia cambogia (Pericarp)    X 
Garcinia Hydroxycitrate Dry Extract    X 
Garlic (Bulb)    X 
Garlic Dry Extract    X 
Garlic Fluidextract    X 
Garlic Oil  X   
Gellan Gum  X X  
Geranium Oil, Algerian Type  X   
Ginger (Rhizome)    X 
Ginger Oil  X   
Ginger Tincture    X 
Ginkgo Leaf X   X 
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Monograph AHP FCC NF USP 
Ginkgo Leaf Dry Extract X   X 
Goldenseal (Root and Rhizome) X   X 
Goldenseal Dry Extract    X 
Grape Seeds Oligomeric Proanthocyanidins    X 
Grape Skin Extract  X   
Grapefruit Oil, Cold-pressed  X   
Green Tea Dry Extract, Decaffeinated    X 
Guar Gum  X X  
Guggul (Oleo-gum-resin)    X 
Guggul Native Extract    X 
Guggul Purified Extract    X 
Gum Ghatti  X   
Gum Guaiac  X   
Gymnema (Leaf)    X 
Gymnema Native Extract    X 
Gymnema Purified Extract    X 
Hawthorn Berry X    
Hawthorn Leaf with Flower X   X 
Holy Basil Leaf    X 
Holy Basil Leaf Dry Extract    X 
Hops Oil  X   
Horse Chestnut Seed    X 
Horse Chestnut Seed Dry Extract    X 
Japanese Honeysuckle Flower    X 
Japanese Honeysuckle Flower Dry Extract    X 
Juniper Berries Oil  X   
Karaya Gum  X   
Kelp  X   
Konjac Flour  X   
Labdanum Oil  X   
Laurel Leaf Oil  X   
Lavandin Oil, Abrial Type  X   
Lavender Oil  X   
Lemon Oil   X  
Lemon Oil, Cold-pressed  X   
Lemon Oil, Desert Type, Cold-pressed  X   
Lemon Oil, Distilled  X   
Lemon Tincture   X  
Lemongrass Oil  X   
Licorice (Root, Rhizome, Stolon)    X 
Licorice Dry Extract    X 
Licorice Fluidextract   X  
Lime Oil, Cold-pressed  X   
Lime Oil, Distilled  X   
Linaloe Wood Oil  X   
Locust (Carob) Bean Gum  X   
Lovage Root Oil  X   
Lutein    X 
Lycium (goji) Berry X    
Lycopene    X 
Lycopene Extract from Tomato  X   
Lycopene from Blakeslea trispora  X   
Lycopene Preparation    X 
Mace Oil  X   
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Malabar-Nut-Tree Leaf    X 
Malabar-Nut-Tree Leaf Dry Extract    X 
Mandarin Oil, Cold-pressed  X   
Maritime Pine (Stem Bark)    X 
Maritime Pine Extract  X  X 
Marjoram Oil, Spanish Type  X   
Marjoram Oil, Sweet  X   
Masticatory Substances, Natural  X   
Mentha arvensis Oil, Partially Dementholized  X   
meso-Zeaxanthin  X  X 
meso-Zeaxanthin Preparation    X 
Milk Thistle (Ripe Fruit)    X 
Milk Thistle Dry Extract    X 
Monk Fruit Extract  X   
Motherwort Aerial Parts X    
Mustard Oil  X   
Myrrh (Oleo-Gum-Resin)    X 
Myrrh Oil  X   
Nutmeg Oil  X   
Olibanum Oil  X   
Olive Leaf    X 
Olive Leaf Dry Extract    X 
Onion Oil  X   
Orange Oil   X  
Orange Oil, Bitter, Cold-pressed  X   
Orange Oil, Cold-pressed  X   
Orange Oil, Distilled  X   
Orange Peel Tincture, Sweet   X  
Orange Spirit, Compound   X  
Orange Syrup   X  
Origanum Oil, Spanish Type  X   
Orris Root Oil  X   
Osha Root X    
Palm Kernel Oil   X  
Palm Kernel Oil (Unhydrogenated)  X   
Palm Oil, Hydrogenated    X  
Palm Oil, Refined   X  
Palm Oil (Unhydrogenated)  X   
Palmarosa Oil  X   
Papain    X 
Parsley Herb Oil  X   
Parsley Seed Oil  X   
Pea Starch  X X  
Pectin    X 
Pennyroyal Oil  X   
Peppermint   X  
Peppermint Oil  X X  
Peppermint Spirit    X 
Peppermint Water   X  
Petitgrain Oil, Paraguay Type  X   
Phyllanthus amarus (Aerial Parts)    X 
Pimenta Fruit Oil  X   
Pimenta Leaf Oil  X   
Pine Needle Oil, Dwarf  X   
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Pine Needle Oil, Scotch Type  X   
Plant Stanol Esters  X  X 
Plantago Seed    X 
Psyllium Husk    X 
Pygeum Bark    X 
Pygeum Bark Extract    X 
Rebaudioside A  X   
Red Clover Aerial Parts    X 
Red Clover Aerial Parts Isoflavone Aglycones Dry Extract    X 
Red Clover Aerial Parts Dry Extract    X 
Red Clover Flowering Tops, Aerial Parts, and Dry Extracts X    
Reishi Mushroom X    
Rhodiola crenulata Root and Rhizome    X 
Rhodiola crenulata Root and Rhizome Dry Extract    X 
Rhodiola rosea Root and Rhizome    X 
Rhodiola rosea Root and Rhizome Dry Extract    X 
Rhodiola rosea Root and Rhizome Tincture    X 
Rose Oil  X X  
Rosemary Extract  X   
Rosemary Leaf    X 
Rosemary Leaf Dry Aqueous Extract    X 
Rosemary Oil  X   
Rose Water, Stronger   X  
Rue Oil  X   
Sage Oil, Dalmatian Type  X   
Sage Oil, Spanish Type  X   
Sandalwood Oil, East Indian Type  X   
Salix Species Bark    X 
Salix Species Bark Dry Extract    X 
Savory Oil (Summer Type)  X   
Saw Palmetto (Ripe Fruit)    X 
Saw Palmetto Extract    X 
Schisandra Berry X    
Schisandra Fruit, Northern    X 
Schisandra Fruit, Northern, Dry Extract    X 
Schizochytrium Oil    X 
Senna Fluidextract    X 
Senna Leaf    X 
Senna Oral Solution    X 
Senna Pods    X 
Sennosides    X 
Sheanut Oil, Refined  X   
Skullcap Aerial Parts X    
Slippery Elm Inner Bark X   X 
Solin Oil  X   
Soy Isoflavones Dry Extract    X 
Spearmint Oil  X   
Spice Oleoresins  X   
Spike Lavender Oil  X   
Spirulina   X  X 
Star Anise Fruit  X    
Steviol Glycosides  X   
Stinging Nettle Herb X    
Stinging Nettle Root X   X 
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Stinging Nettle Root Dry Extract    X 
St. John’s Wort Flowering Top X   X 
St. John's Wort Flowering Top Dry Extract    X 
Storax (Balsam)    X 
Tagetes Extract  X   
Tangerine Oil, Cold-pressed  X   
Tangerine Peel    X 
Tangerine Peel Dry Extract    X 
Tannic Acid (from nutgalls on Quercus tree twigs)  X  X 
Tara Gum  X   
Tarragon Oil  X   
Tea Polyphenols from Green Tea, Decaffeinated  X   
Thyme Oil  X   
Tolu Balsam    X 
Tolu Balsam Syrup   X  
Tolu Balsam Tincture   X  
Tapioca Starch   X  
Tienchi Ginseng Root and Rhizome    X 
Tienchi Ginseng Root and Rhizome Dry Extract    X 
Tomato Extract Containing Lycopene    X 
Tragacanth  X X  
Turmeric (Rhizome)    X 
Turmeric Dry Extract    X 
Turmeric Oleoresin  X   
Uva Ursi Leaf X    
Valerian Root X   X 
Valerian Root Dry Extract    X 
Valerian Root Tincture    X 
Vanilla (Unripe Fruit)   X  
Vanilla Tincture   X  
Vegetable Oil Phytosterol Esters  X   
Wheat Bran    X 
Willow Bark X    
Wintergreen Oil  X   
 
